Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 464.48M |
| Revenue (ttm) | 1.34M |
| Net Income (ttm) | -61.64M |
| Shares Out | 50.27M |
| EPS (ttm) | -1.28 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 437,353 |
| Open | 12.01 |
| Previous Close | 10.14 |
| Day's Range | 9.04 - 9.98 |
| 52-Week Range | 10.70 - 43.26 |
| Beta | 1.24 |
| Analysts | Buy |
| Price Target | 36.00 (+289.6%) |
| Earnings Date | Nov 2, 2021 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic diseases of obesity. The company's lead product candidate is IMCIVREE, a potent melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is also developing setmelanotide, which is in Phase II clinical trials for treating POMC...
Financial Performance
Financial StatementsAnalyst Forecast
According to 8 analysts, the average rating for RYTM stock is "Buy." The 12-month stock price forecast is 36.00, which is an increase of 289.61% from the latest price.
News
Rhythm Pharmaceuticals Announces FDA Acceptance for Filing and Priority Review of Supplemental New Drug Application f...
FDA sets PDUFA goal date of March 16, 2022 FDA sets PDUFA goal date of March 16, 2022
Rhythm Pharmaceuticals Reports Third Quarter 2021 Financial Results
-- U.S. and EU regulatory filings submitted for IMCIVREE ® (setmelanotide) for treatment of Bardet-Biedl and Alström syndromes; launch preparations underway -- -- Delivered a total of 22 presentations a...
Rhythm Pharmaceuticals Presents First-ever Data Showing Improvements in Health-related Quality of Life for Patients L...
-- Additional oral presentation details safety and efficacy data from Phase 3 trial of setmelanotide in BBS -- -- Also presenting new hunger data from SRC1 and SH2B1 cohorts in Phase 2 Basket Trial and ...
Rhythm Pharmaceuticals to Report Third Quarter 2021 Financial Results on Tuesday, November 2, 2021
BOSTON, Oct. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic ...
Rhythm Pharmaceuticals Completes Submission of Type II Variation Application to the European Medicines Agency for IMC...
BOSTON, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company committed to transforming the care of people living with rare genetic ...
Rhythm Pharmaceuticals Presents New Data on Experience of People Living with Rare Genetic Diseases of Obesity and Pro...
-- New data in patients with POMC or LEPR deficiency obesity show setmelanotide led to clinically meaningful improvements in health related quality of life measures and hunger -- -- Updated results fr...
Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic ...
-- New subgroup analysis of Phase 3 data show setmelanotide achieved statistically significant weight loss and hunger reduction compared with placebo at 14 weeks in patients with Bardet-Biedl syndrome -...
CORRECTION: Rhythm Pharmaceuticals, Inc.
BOSTON, Sept. 21, 2021 (GLOBE NEWSWIRE) -- In a release issued on Wednesday, September 21 by Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), please note that the symbol ▼ was erroneously omitted from the h...
Rhythm Pharmaceuticals Announces Marketing Authorisation of IMCIVREE® (setmelanotide) in Great Britain
– IMCIVREE is indicated for treatment of obesity and control of hunger associated with genetically confirmed loss-of-function biallelic pro-opiomelanocortin (POMC), including PCSK1, deficiency or bialle...
Rhythm Pharmaceuticals Completes Submission of Supplemental New Drug Application to U.S. Food and Drug Administration...
BOSTON, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...
Rhythm Pharmaceuticals Announces Expanded Access Program for Setmelanotide for Patients with Bardet-Biedl Syndrome
Expanded access program may allow access for eligible patients in the United States who have no authorized treatment options Expanded access program may allow access for eligible patients in the United ...
Rhythm Pharmaceuticals Announces CMO Transition
-- Linda Shapiro Manning, M.D., Ph.D., promoted to Chief Medical Officer, effective Sept. 10 -- -- CMO Murray Stewart, M.D., to transition to Senior Medical Advisor -- BOSTON, Sept. 02, 2021 (GLOBE NEWS...
Rhythm Pharmaceuticals to Present at Morgan Stanley 19th Annual Global Healthcare Conference
BOSTON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic di...
Rhythm Pharmaceuticals to Present at the 59th Annual ESPE Meeting
Company announces acceptance of seven abstracts with data from multiple clinical trials evaluating setmelanotide for rare genetic diseases of obesity Company announces acceptance of seven abstracts with...
Rhythm Pharmaceuticals, Inc. (RYTM) Upgraded to Buy: Here's Why
Rhythm Pharmaceuticals, Inc. (RYTM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Rhythm Pharmaceuticals Reports Second Quarter 2021 Financial Results
-- Received European Commission authorization of IMCIVREE for treatment of obesity and control of hunger associated with POMC, PCSK1 and LEPR deficiencies -- -- Setmelanotide selected for evaluation as ...
Rhythm Pharmaceuticals Announces Comprehensive Expansion of Clinical Development Program with Five New Phase 2 and 3 ...
-- Pivotal Phase 3 EMANATE trial planned in patients with heterozygous POMC, PCSK1 or LEPR, and SRC1 or SH2B1 deficiency obesities -- -- EMANATE, as well as Phase 2 DAYBREAK trial evaluating setmelanoti...
Rhythm Pharmaceuticals Announces Collaborative Research Agreement with Clinical Registry Investigating Bardet-Biedl S...
Population study to focus on natural history of weight gain, hyperphagia and quality of life in patients with Bardet-Biedl syndrome Population study to focus on natural history of weight gain, hyperphag...
Rhythm Pharmaceuticals to Report Second Quarter 2021 Financial Results on Tuesday, August 3, 2021
BOSTON, July 27, 2021 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic dis...
Rhythm Pharma's Imcivree Gets European Approval For Obesity, Control of Hunger Associated With Genetic Mutations
The European Commission (EC) has approved Rhythm Pharmaceuticals Inc's (NASDAQ: RYTM) Imcivree (setmelanotide) for obesity and the control of hunger. The approval covers obesity associated with genetica...
Rhythm Pharmaceuticals Announces European Commission Authorization of IMCIVREE® (setmelanotide)▼ for the Treatment of...
First-ever authorized treatment option in the European Union for these rare genetic diseases of obesity First-ever authorized treatment option in the European Union for these rare genetic diseases of ob...
Rhythm Pharmaceuticals Receives Positive CHMP Opinion for Setmelanotide for Treatment of Obesity and Control of Hunge...
European Commission decision anticipated in July European Commission decision anticipated in July
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Surpass Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) delivered earnings and revenue surprises of 4600.00% and -99.97%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...
Rhythm Pharmaceuticals Reports First Quarter 2021 Financial Results
-- First U.S. commercial sales of IMCIVREE™ (setmelanotide) completed late in first quarter –
